Login / Signup

Burkitt Lymphoma International Prognostic Index.

Adam J OlszewskiLasse Hjort Kyneb JakobsenGraham P CollinsKate CwynarskiVeronika BachanovaKristie A BlumKirsten M BoughanMark BowerAlessia Dalla PriaAlexey DanilovKevin A DavidCatherine S DiefenbachFredrik EllinNarendranath EpperlaUmar FarooqTatyana A FeldmanAlina S GerrieDeepa JagadeeshManali KamdarReem KarmaliShireen KassamVaishalee P KenkreNadia KhanSeo-Hyun KimAndreas K KleinIzidore S LossosMatthew A LunningPeter MartinNicolás Martinez-CalleSilvia MontotoSeema NaikNeil PalmisianoDavid J PeaceElizabeth H PhillipsTycel Jovelle PhillipsCraig A PortellNishitha M ReddyAnna SantarsieriMaryam Sarraf YazdyKnut B SmelandScott E SmithStephen Douglas SmithSuchitra SundaramAdam Stephen ZayacXiao-Yin ZhangCatherine ZhuChan Yoon Y CheahTarec C El-GalalyAndrew M Evens
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The BL-IPI provides robust discrimination of survival in adult BL, suitable for use as prognostication and stratification in trials. The high-risk group has suboptimal outcomes with standard therapy and should be considered for innovative treatment approaches.
Keyphrases
  • diffuse large b cell lymphoma
  • type diabetes
  • young adults
  • free survival
  • mesenchymal stem cells
  • metabolic syndrome
  • skeletal muscle
  • adipose tissue
  • cell therapy